Ovarian cancer/Fallopian Tube cancer/Primary Peritoneal cancer: Useful in certain circumstances…Pembrozilumab (for microsatellite instability-high [MSI-H] or mismatch repair-deficient [dMMR] solid tumors, or patients with tumor mutational burden-high [TMB-H] tumors ≥10 mutations/ megabase and no satisfactory alternative treatment options).

KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.